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Understanding the behaviour and function of biomolecules at the molecular level is 
key to the discovery and development of new drugs, as well as diagnostic techniques. The 
characterization of therapeutic monoclonal antibodies (mAbs) poses many challenges 
compared to those of low-molecular mass drugs because of their inherent complexity due to 
their protein nature. Achievements in this field of science have changed the way that drugs 
are being designed and developed nowadays. Vibrational spectroscopy techniques, like 
Fourier Transform Infrared (FTIR) spectroscopy and Raman spectroscopy (RS) have helped 
to determine the secondary structure of complex protein molecules, as well as protein-ligand 
complexes. Other advantages of these techniques include the need of very low sample 
concentration and the ease of sample preparation. Therefore, they are gaining growing 
importance in the field of medicine and pharmacology.  
Our group has demonstrated the use of these tools to understand protein-ligand 
interactions in therapeutically important mAb, rituximab, conjugated with three different 
bifunctional chelating agents (p-SCN-Bn-DOTA, p-SCN-Bn-DTPA and 1B4M-DTPA) with 
no available structural information of obtained complexes. A special interest was directed to 
the secondary structure of the antibody. In spite of the fact that Raman spectra show 
characteristic fingerprints which can be used for molecular identification, we detected the 
most important protein groups, and noted the a-helix and the b-sheet structures in the 
molecule.  
The high-throughput approach presented here has significant potential for analyzing 
the stability of biotherapeutics as well as any other biological molecules which are used as 
anti-cancer therapeutic drugs. 
 
 
 
